GeoVax Labs (NASDAQ:GOVX) Releases Quarterly Earnings Results, Beats Expectations By $0.49 EPS

GeoVax Labs (NASDAQ:GOVX) announced its earnings results on Thursday. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.49, Zacks reports. The company had revenue of $3.00 million for the quarter, compared to the consensus estimate of $2.38 million.

GeoVax Labs Trading Down 12.6 %

Shares of GeoVax Labs stock opened at $1.11 on Friday. The business has a 50-day moving average price of $1.67 and a two-hundred day moving average price of $2.14. GeoVax Labs has a 1-year low of $1.09 and a 1-year high of $11.18.

Analyst Ratings Changes

Separately, D. Boral Capital reissued a “buy” rating and issued a $18.00 price target on shares of GeoVax Labs in a research note on Friday. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $14.20.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.